AUG 20, 2021 8:47 AM PDT

Blood Pressure Drugs Boost Survival in Colorectal Cancer

WRITTEN BY: Annie Lennon

Common drugs used to regulate blood pressure may improve survival rates among patients with colorectal cancer, also known as colon cancer. The corresponding study was published in Cancer Medicine by researchers in the US and Brazil. 

Previous studies have found that vascular changes are common in cancers. Furthermore, antihypertensive medications - those that lower blood pressure- have been shown to have an effect on tumors. 

While high blood pressure is common among those with colorectal cancer, there has been little research into the effects of blood pressure medications on patients with colorectal cancer. Researchers thus sought to investigate this topic in the present study. 

To do so, they examined 13,982 colorectal cancer patient outcomes from the Surveillance, Epidemiology, and End-Results (SEER) Medicare database. All patients were aged 65 or older and were diagnosed with the cancer between 2007 and 2012. 

The researchers found that patients using ACE inhibitors and thiazide diuretics benefited most in terms of survival and outcomes. Those on calcium-channel blockers, however, benefited less. Patients who took their blood pressure medications consistently also had lower mortality rates. 

 "Our results show an association between increased adherence to [blood-pressure] medications and reduced … mortality in patients starting these medications after stage I, II or III CRC diagnosis relative to those who did not," wrote the researchers of their findings. 

"It is heartening to note that we could confirm the results of the animal model work done by Dr. Roger Chammas and colleagues at the University of São Paulo Cancer Center in a human population as well," said Rajesh Balkrishnan, one of the authors of the paper. 

"We will continue to explore these protective effects of antihypertensives on other cancers as well in human populations using stronger study designs. This could potentially provide significant implications for gastrointestinal cancer treatment,” he added. 

 

Sources: Cancer MedicineScience Daily

 

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
SEP 24, 2021
Drug Discovery & Development
WHO Recommends Antibody Treatment for High Risk COVID-19 Patients
SEP 24, 2021
WHO Recommends Antibody Treatment for High Risk COVID-19 Patients
The World Health Organization (WHO) has recommended a combination of two antibody treatments for patients at risk of adv ...
SEP 24, 2021
Drug Discovery & Development
Nasal Drugs Show Promise for Slowing Parkinson's Disease
SEP 24, 2021
Nasal Drugs Show Promise for Slowing Parkinson's Disease
Two drugs delivered via the nose have shown promise for improving symptoms of Parkinson's disease in mice. The corre ...
OCT 04, 2021
Genetics & Genomics
Zaki syndrome - Pediatric Disorder & Potential Treatment ID'ed
OCT 04, 2021
Zaki syndrome - Pediatric Disorder & Potential Treatment ID'ed
Since it's become quick and relatively inexpensive to sequence a human genome, researchers have gained unprecedented and ...
OCT 21, 2021
Drug Discovery & Development
Cholesterol Drug Regrows Neurons After Spinal Cord Injury
OCT 21, 2021
Cholesterol Drug Regrows Neurons After Spinal Cord Injury
Fenofibrate, an FDA-approved drug used to reduce cholesterol levels, causes sensory neurons in the spine following spina ...
NOV 03, 2021
Plants & Animals
A Samoan Plant May Reduce Inflammation as Well as Ibuprofen
NOV 03, 2021
A Samoan Plant May Reduce Inflammation as Well as Ibuprofen
To the people of Samoa, the medicinal qualities of a tree known as matalafi are well known. Now scientists are bringing ...
NOV 14, 2021
Genetics & Genomics
Cancer Drug Target Could Actually Worsen Disease
NOV 14, 2021
Cancer Drug Target Could Actually Worsen Disease
Cancer drugs have been developed that target an enzyme, Shp2. But that enzyme has a more complex role than we knew.
Loading Comments...